DBV Technologies (DBVT) Share-based Compensation (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Share-based Compensation of $3.7 million for Q2 2026, up 208.33% year-on-year from $1.2 million in Q2 2025, and up 60.87% on a QoQ basis from $2.3 million in Q1 2026.
DBV Technologies (DBVT) Share-based Compensation (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Share-based Compensation for 7 consecutive years, with $3.7 million the latest figure, recorded in Q2 2026.
- Quarterly Share-based Compensation rose 208.33% year-over-year to $3.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.5 million (up 110.23% YoY) and the FY2025 annual result came in at $5.4 million, up 16.6% from the prior year.
- Share-based Compensation advanced to $3.7 million in Q2 2026 per DBVT's latest filing, from $2.3 million in the prior quarter.
- Over the last five years, Share-based Compensation for DBVT reached as high as $3.7 million in Q2 2026 and fell as low as -$453000.0 in Q4 2024.
- A 5-year average of $1.5 million and a median of $1.6 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 137.16% — and 2025, when it surged 524.72%.
- Year by year, Share-based Compensation stood at $1.6 million in 2022, then declined by 24.29% to $1.2 million in 2023, then slumped by 137.16% to -$453000.0 in 2024, then jumped by 524.72% to $1.9 million in 2025, then soared by 92.31% to $3.7 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.7 million, $2.3 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70 Mn |
| Jun 30, 2026 | 3.70 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 563,000.00 |
| Sep 30, 2025 | 563,000.00 |
| Jun 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -453,000.00 |
| Dec 31, 2024 | -453,000.00 |
| Sep 30, 2024 | 1.59 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.96 Mn |